We have recently found that intravenous immunoglobulin (IVlg) prevents deposition of C3 and C4 fragments onto antibody sensitized erythrocytes. To find out if such an effect results from the blockade of the recognition phase of the classical complement cascade, we investigated the ability of human serum containing high concentrations of lVlg to deposit the recognition subunit of the first complement component (Clq) onto targets. Normal human serum supplemented in vitro with lVlg did not demonstrate reduced Clq binding to targets as determined by radiolabeled antihuman Clq antibody uptake. Similarly, methylamine-treated normal human serum to which IVlg was added was equally effective HE FIRST component of the classical complement T cascade (Cl) is considered as two structurally and functionally distinct proteins: Clq, the recognition subunit; and (ClrCls),, the catalytic subunit, which is a calciumdependent tetrameric association of the two serine protease proenzymes Clr and Cls. ' The initial stage in the activation of the complement system via classical pathway involves interaction between the recognition subunit of C1 and a complement binding site on Ig molecules. It is believed that Clq binding induces conformational changes in the C1 complex resulting in conversion of C l r to an enzyme capable of activating Cls, which in turn acts on its substrates C2 and C4, allowing continuation of the cascade.' Intravenous (IV) Igs at high doses are known to have beneficial effects in a variety of autoimmune diseases:' but mechanisms by which these effects are mediated remain incompletely elucidated. We have proposed that IVIg exerts at least a portion of its effect by inhibiting the binding of C4 and C3 to targets6.* Because inhibition of C3 and C4 uptake may well result from the blockade of the recognition (Clq) stage, we wanted to examine the effect of IVIg on Clq binding to further elucidate the exact mechanism of effect of IVIg on the classical complement system.
in terms of Clq binding as the same serum without IVlg. At increasing doses of sensitizing antibody, Clq uptake decreased proportionally; however, at all antibody dilution points Clq uptake was not significantly different in the serum with lVlg in comparison with normal serum. Serum from a patient treated with lVlg did not differ in its capacity to deposit Clq from the same patient's serum before therapy. Our data suggest that lVlg does not interfere with the recognition step of classical complement pathway. This is a US government work. There are no restrictions on its use.
Buffers. Isotonic Veronal-buffered saline containing 0.1% gelatin, 0.15 mmol/L Ca2+, and 1 mmollL M$+ (GVBS"), isotonic Veronal-buffered saline (VBS) containing 0.1% gelatin and 10 mmol/L EDTA, isotonic VBS, and Veronal-buffered isotonic sucrose (9.72% wtivol) containing 0.1% gelatin, 0.15 mmol/L Ca2+, and 1 mmollL M$' were prepared as previously described." A 60:40 mixture of this last buffer and GVBS2' was used in some experiments (SGVBS'+).
Goat antihuman Clq antibody was radioiodinated using Iodobeads (Pierce, Rockford, IL) following the directions supplied by the manufacturer. Four hundred micrograms of the antibody was incubated with 1 mCi of I2'I and three iodobeads for 30 minutes at room temperature. Free iodine was separated from protein-bound isotope by passing the labeled material through a prepacked PD 10 (Sephadex G-25M) column (Pharmacia Fine Chemicals, Freehold, NJ) in isotonic phosphate-buffered saline (PBS), pH = 7.4.
Hemolytic complement titrations of human C3, C4, and C1 were performed using standard published procedures. ' Fresh normal human serum was obtained by clotting the blood drawn from a single donor at 37°C for 15 minutes. Cells were separated by centrifugation for 5 minutes at 3,000 rpm.
Serum was incubated with sufficient methylamine solution (10 m o m ) to achieve a final concentration of 100 mmol/L for 2.5 hours at -30°C with occasional shaking. The methylamine serum was dialyzed 2 x12 hours at 4°C against VBS and stored as 2-mL samples at -70°C until use. 10M Methylamine solution, 10 mol/L, was made by dissolving 1.35 g of methylamine hydrochloride in 2 mL of dH,O and titrated to pH = 7.8 with 2 mol/L NaOH.
Human serum Ig for IV use in 10% maltose, pH = 4.25 (Gamimune) and human serum albumin 25% solution for IV administration were purchased from Cutter Biologicals (Berkeley, CA). Methylamine hydrochloride was purchased from Sigma (St Louis, MO).
Normal donor blood was collected into an EDTA-containing evacuated tube. RBCs were separated from EDTA plasma, washed, and standardized to 3.3 X 10' cells/mL in GVBS". Three hundred microliters of the above human RBC suspension were incubated with 0.3 mL of diluted rabbit IgG antihuman RBC antibody (EA), or 0.3 mL of buffer (E) for 30 minutes at 37°C. After two washes in GVBS2', pellets of sensitized erythrocytes were resuspended in 250 pL of autologous human serum, autologous human serum supplemented with IVIg (5 mg/tube), and autologous human serum supplemented with human albumin in 10% maltose (5 mgitube). The E pellet was resuspended in normal human serum. The tubes were then placed Radiolabeling.
Complement titrations.
Methylamine serum.
Other reagents.
In vitro C l q uptake studies. C l q uptake in the presence of methylamine-treated serum. Autologous human serum was treated with methylamine to destroy functional activity of complement components bearing the thiolester bond C3 and C4. Complement functional assays for C3, C4, and C1 showed that methylamine treatment brought functional activity of C3 and C4 to virtually zero; C1 levels in this serum were reduced by 50%. IgG-sensitized erythrocytes were targets in the Clq uptake study in which methylamine-treated serum (MTS) was used as a source of complement. Addition of 5 mg of IVIg per tube to MTS did not alter the magnitude of Clq binding relative to MTS without IVIg, as determined by the incorporation of radiolabeled antihuman Clq (Table 1) .
C l q uptake onto human erythrocytes sensitized with different dilutions of antihuman RBC antiboa!y. Human RBCs were sensitized with antihuman RBC IgG antibody diluted 1:1,000, 1:1,500, 1:2,000, and 1:4,000. EA pellets were C l q uptake onto IgG-sensitized human erythrocytes. Normal human serum and methylamine-treated human serum with or without added lVlg (5 mg/tube) served as the source of complement for Clq uptake studies in which homologous human RBCs sensitized with rabbit antihuman RBC IgG antibodies were targets. Following a 15-minute incubation at 30°C. triplicate aliquots were removed for Clq uptake quantification by antihuman C l q IgG labeled with lZ5l. Addition of lVlg to normal or methylamine-treated serum did not affect C l q binding to targets.
1).
Abbreviations: MTS IVlg, methylamine-treated serum with added IVlg; MTS, methylamine-treated serum; NS IVlg, normal human serum with added IVlg; NS, normal human serum. incubated with autologous human serum with and without IVIg at 5 mg/tube. Clq uptake decreased proportionally to the increase in dilution of sensitizing antibody; however, serum supplemented with IVIg at all antibody dose points gave unaltered Clq uptake compared to the serum without IVIg (Fig 1) .
C l q uptake in the presence of increasing doses of Wig. IgG-sensitized human erythrocytes were incubated with autologous serum containing 5, 10, 15, and 20 mg of IVIg. After a 15-minute incubation at 30"C, C l q uptake was quantified by incorporation of '=I-labeled antihuman C l q IgG. Clq uptake was not altered over the entire range of increasing levels of IVIg (Fig 2) . For
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Clq uptake in the presence of serum from an Nlg-treated patient. Human RBCs were sensitized with rabbit antihuman RBC IgG antibody and incubated with undiluted serum from a patient treated with IVIg and the same patient's serum sample before IVIg therapy. After a 15-minute incubation at 30°C, cell aliquots were taken for Clq uptake quantification by antihuman Clq IgG antibody labeled with IuI. In comparison with the same sample before IVIg therapy, posttreatment serum showed undiminished Clq uptake onto sensitized homologous erythrocytes (Fig 3) .
DISCUSSION
We have previously shown that IVIg modifies complement-dependent immune injury in two in vivo models: clearance of IgM-sensitized erythrocytes6 and Forssman
We also used in vitro complement uptake studies to define at what sites IVIg interferes with the classical complement pathway. Activated C3 and C4 fragment uptake was inhibited to the same extent, suggesting that IVIg may act at multiple steps along the pathway:
In this study we present evidence that high doses of IVIg do not affect the recognition step of the classical complement pathway, ie, binding of Clq to sensitized targets. That conclusion has been reached by approaching the issue in several different ways. Normal human serum with and without added IVIg was equally effective in terms of Clq binding to IgG-sensitized erythrocytes. Uptake of nascent C4b and C3b onto immune complexes strongly modulates C1 consumption in serum." The mechanism of this effect has not been fully elucidated, but we wished to rule out the possibility that depression of C4b and C3b uptake by IVIg might be secondarily masking an effect on Clq binding. Thus, we treated human serum with methylamine to remove functional activity of C3 and C4. This maneuver had no effect on Clq binding because it was the same both in the presence and absence of high doses of IgG. Similarly, serum from a patient treated with IVIg did not show reduced uptake of Clq in comparison with the same patient's serum before therapy, even though these same sera have previously been documented to have impaired C4 uptake in the posttherapy specimens.' We are aware of no previous studies dealing with the binding of Clq to sensitized targets in the presence of supraphysiologic levels of IgG. Segal et al" have mathematically modeled binding of Clq to antibody-coated cells in the presence of varying amounts of monomeric IgG; their calculations predicted that IgG will inhibit the binding of Clq to antibody-coated targets. They showed in an in vitro model that complement lysis of nucleated cells could indeed be inhibited by high doses of exogenous IgG. However, the experiment did not localize the effect of C1 step, nor did the mathematically predicted extent of C1 binding inhibition account for the majority of lysis inhibition noted, especially with heavily sensitized targets.
Our present findings seem to limit the number of possible sites of interference of IVIg with the classical complement cascade. It appears that further research should focus on the nature of interaction between ambient or exogenous IgG and thiolester-bearing complement components C3 and C4.
